News and Insights of 3D Printing and Manufacturing
Finnish bioprinting startup Brinter released the new extrusion-based Visco Bio medical print head for its Brinter bioprinters. The new modular print heads enable nearly zero dead volume, meaning that expensive medical grade material waste is cut to a minimal level. The Finnish company continues to develop and implement new features to its device on the back of a strong first year’s growth year in 2021.
Carl Zeiss Meditec, one of the world’s leading medical technology companies, and Precise Bio, a regenerative medicine company advancing the use of bio-printed tissues and organs, have entered into a partnership to develop and commercialize fabricated corneal tissue for transplants in patients that require endothelial keratoplasty and natural lenticule transplants for treating keratoconus and vision correction.
Humabiologics, an industry leader in providing human-derived biomaterials for regenerative medicine, founded by scientists and tissue industry experts to address the gap between the gift of donated human tissues and researchers, and Fisher Scientific, a global leader in life sciences, are partnering to serve researchers in academia and industry who are working on regenerative medicine research.
Bioprinter manufacturer REGEMAT3D is launching a new equity crowdfunding round, that will help the company further scale its business and product lines while preparing for an IPO set to take place in 2023. At 3dpbm we usually do not cover crowdfunding campaigns for new products, however, this initiative is relative to a company that is already present in the market and has been making significant progress in the bioprinting segment. REGEMAT3D promises massive returns (up to 3 to 4 times the investment) and while the actual success of this financial initiative is subject to the same risks as any financial venture, the overall bioprinting segment is in fact growing up rapidly.
The PhonoGraft biomimetic hearing-restoration technology, advanced through a six-year effort by a multidisciplinary research team at the Wyss Institute for Biologically Inspired Engineering, Harvard’s John A. Paulson School of Engineering and Applied Sciences (SEAS), and Massachusetts Eye and Ear (MEE)/Mass General Brigham (MGB), has now entered commercial development. If successful, it could mitigate pain, drainage, and hearing loss associated with eardrum perforations that affect millions of individuals worldwide.